About this Research Topic
Cancer continues to be a formidable challenge globally, with traditional drug discovery methods focusing on cytotoxic agents and targeted therapies altering the landscape of cancer prognosis and treatment. Despite these advances, achieving long-term therapeutic responses remains difficult due to tumor heterogeneity and resistance to targeted therapies, which hinders dosage effectiveness, diminishes treatment efficacy, and affects overall clinical outcomes. This underscores the critical need for novel therapeutic strategies that can effectively control and potentially reverse carcinogenesis.
This Research Topic is centered on CRISPR-Cas9, a groundbreaking gene-editing technology that has transformed the cancer drug discovery landscape by enabling precise and efficient manipulation of genetic targets. Through techniques such as gene knock-out, knock-in, and transcriptional modulation, CRISPR-Cas9 offers a direct approach to identify and validate new drug targets, accelerating the development of cancer therapies. As this technology advances, it is imperative to capture the latest discoveries, address current gaps, and discuss future directions in the application of CRISPR-Cas9 for cancer drug discovery.
In an effort to enrich the discourse and scope of research in this field, we are seeking submissions that include but are not limited to the following topics:
• CRISPR/Cas9 methodologies in drug screening, including gene knock-outs, knock-ins, and transcriptional modifications.
• Applications of CRISPR-Cas9 in targeted delivery systems such as nanoparticles and peptide carriers for cancer therapy.
• The potential of CRISPR/Cas9 to innovate future drug development.
• Strategies using CRISPR/Cas9 to combat drug resistance in cancer.
• Utilizing CRISPR/Cas9 libraries for identifying novel drug targets.
• Explorations of CRISPR/Cas9 in cancer immunotherapy and transgenic animal model development.
• Real-world applications of CRISPR/Cas9 in clinical trials and cancer drug validation.
Submissions can include Original Research, Reviews, Mini-reviews, Clinical Trial results, and Perspectives that highlight the impact and potential of CRISPR-Cas9 in the next generation of cancer drug discovery. Contributions should strive to link genomic editing capabilities with practical, clinical applications to forge new pathways in cancer treatment.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of the scope of this section and will not be accepted as part of this Research Topic.
This Research Topic is centered on CRISPR-Cas9, a groundbreaking gene-editing technology that has transformed the cancer drug discovery landscape by enabling precise and efficient manipulation of genetic targets. Through techniques such as gene knock-out, knock-in, and transcriptional modulation, CRISPR-Cas9 offers a direct approach to identify and validate new drug targets, accelerating the development of cancer therapies. As this technology advances, it is imperative to capture the latest discoveries, address current gaps, and discuss future directions in the application of CRISPR-Cas9 for cancer drug discovery.
In an effort to enrich the discourse and scope of research in this field, we are seeking submissions that include but are not limited to the following topics:
• CRISPR/Cas9 methodologies in drug screening, including gene knock-outs, knock-ins, and transcriptional modifications.
• Applications of CRISPR-Cas9 in targeted delivery systems such as nanoparticles and peptide carriers for cancer therapy.
• The potential of CRISPR/Cas9 to innovate future drug development.
• Strategies using CRISPR/Cas9 to combat drug resistance in cancer.
• Utilizing CRISPR/Cas9 libraries for identifying novel drug targets.
• Explorations of CRISPR/Cas9 in cancer immunotherapy and transgenic animal model development.
• Real-world applications of CRISPR/Cas9 in clinical trials and cancer drug validation.
Submissions can include Original Research, Reviews, Mini-reviews, Clinical Trial results, and Perspectives that highlight the impact and potential of CRISPR-Cas9 in the next generation of cancer drug discovery. Contributions should strive to link genomic editing capabilities with practical, clinical applications to forge new pathways in cancer treatment.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of the scope of this section and will not be accepted as part of this Research Topic.
Keywords: Cancer drug discovery, Drug sensitivity/Resistance, Cancer treatment, Gain-of-function/Loss-of-function, Immune therapy, CRISPR/Cas9
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
